The drugmaker is looking at a big year: Sales expectations for its new diabetes medication, Mounjaro, could prove conservative, and the drug’s approval for treating obesity might add to the company’s growth. New drugs for cancer, psoriasis and ulcerative colitis should also boost sales. But the outlook for its Alzheimer’s drug and marketing costs present risks, especially if therapy launches start slowly.
